News

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide.

Grenova and its division partners are backed by healthcare-focused private equity firm Peloton Equity.

Hull brings more than 30 years of leadership experience in the life sciences and diagnostics industries and has served on the Grenova Board of Directors for the past 13 months. He previously served as CEO of Bako Diagnostics and Genova Diagnostics – a former FFC company, Peloton’s predecessor firm – and has worked closely with Peloton Equity as an operating partner.

“Given the increasing demand for automation across laboratory workflows, this is a particularly exciting time to build a scaled, integrated platform in this space. Grenova, Peak Robotics, and PAA each bring world-class capabilities in their respective fields, creating a unique set of solutions for our customers,” said Ted Hull. “I’m incredibly excited to work alongside this team to shape the future of scientific automation.”

“We’re thrilled to partner with Ted again,” said Michael O’Rourke, Partner at Peloton Equity. “Ted brings a rare combination of operational leadership, industry expertise, and a deep understanding of how to scale growth companies. Having worked closely with the company and served alongside the leadership team, he is uniquely positioned to lead this next phase of growth.”

With the combined capabilities of Grenova’s technologies and the automation and integration expertise of Peak Robotics and PAA, the organization is positioned to deliver modular, scalable solutions and become a global leader in laboratory automation.

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia. …

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three …

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and …